Mavacamten
Brand name: Camzyos
Rank #328 of 500 drugs by total cost
$32.8M
Total Cost
3,969
Total Claims
$32.8M
Total Cost
139
Prescribers
$8,270
Cost per Claim
233
Beneficiaries
3,998
30-Day Fills
$236K
Avg Cost/Provider
29
Avg Claims/Provider
About Mavacamten
Mavacamten (sold as Camzyos) was prescribed 3,969 times by 139 Medicare Part D providers in 2023, costing the program $32.8M. At $8,270 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 325 | Dorzolamide Hcl/Timolol Maleat (Dorzolamide-Timolol) | $33.5M | 1,096,480 |
| 326 | Morphine Sulfate (Morphine Sulfate Er) | $33.2M | 1,023,056 |
| 327 | Budesonide (Budesonide Dr) | $33.1M | 120,202 |
| 328 | Mavacamten (Camzyos) | $32.8M | 3,969 |
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology